Search

How to create queries in the free text search:

  • Add double quotes around a group of words to search for pages containing that group (e.g. "fuel cells")
  • AND (or &&):  wind AND "solar panels" returns pages containing both "wind" and "solar panels".
  • OR (or a space): wind "solar panels" returns pages containing wind or "solar panels".
  • NOT (or !): solar NOT "solar panels" returns pages containing solar but not "solar panels".
  • Use the various filters (left column) to refine or reset your search.
  1. Healthcare quality

    Healthcare quality is the extent to which health services provided to individuals and patient populations improve desired health outcomes. Care should be evidence-based and provided in a technically and culturally competent manner with good communication ...

    29 June 2016

  2. Medical applications of radionuclides and targeted alpha therapy

    Cancer is one of the main health problems of today. Unfortunately, the treatments that are currently available, even though often effective, cannot permanently cure the majority of cancers. This is typically true for cancers that have formed metastases an ...

    01 September 2015

  3. Radioimmunoconjugates for targeted alpha therapy

    The present radioimmunoconjugate combines an alpha-emitting radioisotope (e.g. Tb-149, At-211, Bi-212, Bi-213 or Ac-225) with a monoclonal antibody against the MUC-1 receptor. A merit of the present invention is to have found a specific combination of rad ...

    30 May 2016

  4. Method for producing Ac-225 by irradiation of Ra-226 with protons

    The invention proposes a method that allows reducing or even eliminating the waiting period necessary to eliminate undesired radionuclides, especially Ac-224 and Ac-226, which come from the irradiation of Ra-226 by a proton beam. This method supplies a hi ...

    30 May 2016

  5. Radionuclides for medical use

    The most appropriate pair would be pure alpha-emitters with high cumulative energy providing a high cytotoxic dose to targeted cells as well as allowing imaging of the biodistribution of the nuclides in the body and a stable binding to biological carrier ...

    20 May 2016

  6. Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer

    The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate 225Ac linked-trastuzumab delivered through the intraductal ( ...

    15 July 2016

  7. European Commission Initiative on Breast Cancer – ECIBC: Organisation of project guiding and support meetings report- 2015

    The European Commission Initiative on Breast Cancer (ECIBC) aims to sustainably ensure and harmonise quality of breast cancer services across European countries. In order to develop the ECIBC project in a coordinated, consensus-based and sustainable way, ...

    15 July 2016

  8. Analysis of carcinogenicity testing for regulatory purposes in the European Union

    The approaches for evaluating the carcinogenic potential of substances, including whether carcinogenicity studies should be conducted, differ substantially across sectors. Despite variations in testing schemes, the two-year bioassay study in rodents repre ...

    30 June 2016

  9. The European Nanomedicine Characterisation Laboratory launches first call for innovative nanomedicines in cancer therapy

    17 Mar 2016 The use of nanotechnology in healthcare promises new diagnostic opportunities and innovative therapeutic concepts that may help to tackle major medical challenges such as cancer, neurodegenerative diseases and antimicrobial resistance.   Howev ...

    17 March 2016

  10. Plenary of the ECIBC 2015: Improving breast cancer screening, diagnosis and care in Europe

    09 Dec 2015 to 11 Dec 2015 The European Commission Initiative on Breast Cancer (ECIBC) is built upon the principles of sustainability, continuity and the transparent inclusion of experts and stakeholders to develop a project that will have an impact on br ...

    26 November 2015

  11. Alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma multiforme

    Objectives: Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor, and has one of the worst prognoses among the various carcinomas, with a 5-year survival rate of ∼10%. The median survival time is 14.6 months from time of diag ...

    15 July 2016

  12. Ac-225-PSMA617- a single center experience of 40 patients receiving PSMA-targeted alpha therapy

    OBJECTIVES: A case series of 40 patients with advanced stage metastatic castration resistant prostate cancer (mCRPC) treated with alpha-particle emitting Ac-225-PSMA617 was retrospectively evaluated for treatment toxicity and anti-tumor-activity and compa ...

    15 July 2016

  13. 213Bi-labeled PSMA-targeting agents for alpha radionuclide therapy of prostate cancer

    Introduction: Prostate specific membrane antigen (PSMA) is a valuable target for specific delivery of diagnostic and therapeutic radionuclides to prostate tumors. Up to now, PSMA-targeted radionuclide therapy strategies have mainly focused on beta-emittin ...

    25 June 2016

  14. How to promote fruit and vegetable consumption in schools: a toolkit

    Schools are a key environment to teach children healthy eating, thus helping them to form long-term positive dietary behaviours. School-based interventions can reach large groups of children of all social classes, and messages learned may be taken home to ...

    03 June 2016

  15. World cancer day – JRC contribution to the fight against cancer

    04 Feb 2016 Cancer is one of the main causes of death in the EU, responsible for almost 1.3 million deaths in 2013, according to Eurostat. The JRC's work on cancer focuses on developing harmonised data on cancer incidence in the EU, development and p ...

    04 February 2016

  16. Radioimmunothérapie alpha Principes et intérêts en immunité antitumorale

    Alpha-radioimmunotherapy (α-RIT) is a targeted anti-tumor therapy using usually a monoclonal antibody specific for a tumor antigen that is coupled to an α-particle emitter. α-emitters represent an ideal tool to eradicate disseminated tumors or metastasis. ...

    24 June 2016

  17. European Quality Assurance Scheme for breast cancer services- kick-off meeting

    09 Sep 2015 to 11 Sep 2015 The JRC coordinates the European Commission Initiative on Breast Cancer (ECIBC) that foresees the development of a voluntary European Quality Assurance Scheme for breast cancer services based, whenever possible, on evidence (obt ...

    20 October 2015

  18. European guidelines for breast cancer screening and diagnosis- kick-off meeting

    07 Sep 2015 to 09 Sep 2015 The JRC coordinates the European Commission Initiative on Breast Cancer (ECIBC) that foresees the development of a voluntary European Quality Assurance Scheme for breast cancer services based, whenever possible, on evidence (obt ...

    05 October 2015

  19. Breast cancer: new steps towards harmonisation and quality of screening and care in Europe

    05 Jan 2016 The plenary of the European Commission Initiative on Breast Cancer (ECIBC) entitled 'Improving breast cancer screening, diagnosis and care in Europe' took place in Baveno, Italy on 9-11 December 2015. The plenary focused on improving ...

    05 January 2016

  20. The need for a rapid and comprehensive adoption of the revised European standard population in cancer incidence comparisons

    As cancer incidence varies according to age, it is important to rule out differences in age structures in any comparison. A common way of adjusting for these differences is using direct age standardization, which applies age-specific weights from a standa ...

    14 May 2016

  21. Defining the roadmap towards revision of ENCR coding standards and training for cancer registries

    The European Network of Cancer Registries (ENCR) and the Joint Research Centre (JRC) jointly support harmonising the activities of the European population-based cancer registries (CR) in providing reliable and valid data on cancer. The process to supply v ...

    17 June 2016

  22. Targeted Radiolabeled Compounds in Glioma Therapy

    Malignant gliomas of WHO grades II-IV represent the largest entity within the group of intrinsic brain tumors and are graded according to their pathophysiologic features with survival times between more than 10 years (WHO II°) and only several months (WHO ...

    24 June 2016

  23. Ac-225-PSMA617 PSMA-gerichtete Alpha-Strahler-Therapie des metastasierten Prostatakarzinoms

    Ziel: Vergleich des bildgebenden und laborchemischen Therapieansprechens, sowie der klinischen und hämatologischen Nebenwirkungen einer gezielten Radionuklidtherapie des Prostatakarzinoms mit entweder Beta-Strahler markiertem Lu-177-PSMA617 oder Alpha-Str ...

    23 June 2016

  24. JRC Annual Report 2015

    Discover the work of the JRC in 2015 in our online annual report Report on the activities, accomplishments and resources related to the JRC’s work carried out in 2015. An overview is given of the scientific achievements and activities. lbna27501enn_new_2. ...

    14 May 2016

  25. CERN and the JRC to scale up production of alpha-emitters against cancer

    23 Sep 2015 A novel, accelerator-driven method could produce nuclides for targeted alpha therapy of cancer in practically unlimited amounts, overcoming current obstacles for its wider use due to a limited production of alpha-emitters. The JRC and the Cons ...

    23 September 2015